Hyundai Oilbank to file for listing, joining IPO parade next year Korean refiner will file for IPO in December with target of listing in first half of 2022
Translated by Ryu Ho-joung 공개 2021-11-26 08:21:11
이 기사는 2021년 11월 26일 08:19 thebell 에 표출된 기사입니다.
Hyundai Oilbank, the refinery unit of South Korea’s Hyundai Heavy Industries Group, plans to file for an initial public offering in December, with a target of listing in the first half of 2022, as it seeks to embrace eco-friendly hydrogen energy business and its financial performance has rebounded this year.The move would come four months after the refiner named KB Securities, NH Investment & Securities and Credit Suisse as its lead underwriters for the planned IPO in August.
Hyundai Oilbank is expected to get the green light from the Korea Exchange as soon as February next year given that it normally takes two months, or 45 business days, for review.
This means the refiner will join a crowded IPO pipeline in the first half of 2022, with candidates including battery maker LG Energy Solution, SM Line, Hyundai Engineering and car-sharing unicorn startup SoCar.
The refinery business is the company’s mainstay, contributing nearly 85% to its total revenue. Hyundai Oilbank holds a roughly 20.9% share in the domestic light oil market. Comparable companies include SK Innovation, S-Oil and GS Caltex.
Reliance on fossil fuels has been cited as one of the factors that could limit Hyundai Oilbank’s future growth as the transition to zero carbon accelerates, prompting the company to expand into new business areas.
In March this year, Hyundai Oilbank announced a plan to reduce its revenue reliance on the refining business to 45% by 2030 and instead expand profits from future growth drivers, including low-carbon blue hydrogen, white biotechnology and eco-friendly chemical materials. Hyundai Oilbank is the only refiner in the country to have such a transition plan.
It will be difficult for Hyundai Oilbank to make visible progress by the first half of next year. But its equity story, focused on growth in hydrogen energy, could help to increase its growth prospects.
Hyundai Oilbank will set up the infrastructure to capture and utilize carbon dioxide emitted during hydrogen generation processes. It also plans to develop fuel cell separators for hydrogen fuel cell vehicles and roll out products in 2023.
In April this year, Hyundai Oilbank teamed up with hydrogen supplier Air Products to work together to produce hydrogen from crude oil byproducts and natural gas. It also announced a partnership with Korea South-East Power in May to enter the hydrogen power generation market.
Hyundai Oilbank first attempted to go public in 2012 but failed due to a slump in oil prices. Another IPO attempt was also pulled due to accounting issues in 2017.
In 2019 Hyundai Heavy Industries Holdings, the refiner’s parent company, sold a partial stake in Hyundai Oilbank to Saudi’s Aramco in a deal that valued the company at roughly 8.09 trillion won. Given this latest valuation, Hyundai Oilbank will be seeking a valuation above 10 trillion won in the IPO, industry watchers said.
Hyundai Oilbank recorded revenue of 13.7 trillion won in 2020, down by 35.2% from 21.1 trillion won a year ago. It also swung to an operating loss of 593.3 billion won from a 522 billion won operating profit in the same period. However, its financial results have rebounded this year, with revenue and operating profit rising to 14.7 billion won and 851.6 billion won, respectively, in the first three quarters of 2021. (Reporting by Chan-mi Oh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [동구바이오제약 신사업 전략]캐시카우만으론 역부족, 벌크업 기반 '오너 보증 차입'
- [LK삼양 뉴비기닝]그룹 오너 구본욱의 변신, 경쟁력 강화만 본다
- [루키 바이오텍 in market]김권 셀비온 대표"경쟁약 넘는 효능, 품목허가 꿈 도전"
- [Policy Radar]바이오시밀러 문턱 낮춘 유럽, 비용·경쟁 판이 바뀐다
- [보험사 IFRS17 조기도입 명암]MG손보, 자본잠식 벗어났지만 결손금 두 배 늘었다
- [한국투자캐피탈]6년 만에 사내이사 신규 선임…사내이사 2인 체제로
- [이사회 분석]OSB저축, 장찬 신임 대표 이사회 '재정비'
- [금융지주 해외은행 실적 점검]갈 길 바쁜 농협은행…캄보디아 법인 '역성장'
- [이사회 모니터]BNP파리바-신한금융 합작경영 상징 '이사회 쿼터'
- [보험사 IFRS17 조기도입 명암]흥국생명, 'IFRS17' 도입에도 자본 우려 못 지웠다